Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Edgewise Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
15
32.2
54
90.9
127
151
General and administrative
2.21
11
17.6
23.5
31.9
40
Operating expenses
17.2
43.2
71.7
114
159
191
Operating income
-17.2
-43.2
-71.7
-114
-159
-191
Interest income
0.07
0.4
4.02
14.2
25
23.6
Pre-tax income
-100
-134
-168
Income tax
0
0
0
0
0
Net income
-17.1
-42.8
-67.6
-100
-134
-168
EBITDA
-17
-42.9
-71.3
-113
-157
-189
EPS, basic
-23.17
-1.14
-1.26
-1.57
-1.45
-1.63
EPS, diluted
-23.17
-1.14
-1.26
-1.57
-1.45
-1.63
Shares, basic (weighted)
0.74
37.5
53.6
63.7
92.4
103
Shares, diluted (weighted)
0.74
37.5
53.6
63.7
92.4
103
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
105
15.6
22
86.1
41.7
61.1
Other current assets
0.55
2.98
5.05
8.6
5.31
13.3
Total current assets
130
284
357
327
475
543
Property, plant and equipment
0.52
0.91
8.53
10.4
9.5
7.83
Lease right-of-use assets
1.32
2.25
1.57
1.39
Other non-current assets
0.98
0.55
0.25
0.35
0.26
Total assets
131
285
367
340
487
553
Accounts payable
1.58
3.84
6.11
4.03
5.58
6.01
Accrued liabilities
1.59
3.88
5.84
6.07
7.23
7.92
Total current liabilities
4.34
10.5
16.6
16.8
23.9
27.4
Lease liabilities
3.8
4.43
3.74
2.98
Other non-current liabilities
0.33
Total liabilities
4.34
10.9
20.4
21.2
27.6
30.3
Paid-in capital
0.73
352
493
563
837
1,068
Retained earnings
-34.1
-77
-145
-245
-379
-546
Other comprehensive income
-0.51
-1.36
0.1
0.42
0.68
Shareholders' equity
-33.4
274
347
319
459
522
Total equity
-33.4
274
347
319
459
522
Total liabilities and equity
131
285
367
340
487
553
Shares outstanding
1.01
49.5
63.3
70.5
94.8
106
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-17.1
-42.8
-67.6
-100
-134
-168
Depreciation and amortization
0.19
0.27
0.37
1.55
2.07
2.08
Stock-based compensation
0.35
4.4
10.9
17.6
24.7
34.8
Change in payables
0.52
2.65
0.05
-0.09
1.74
0.27
Cash from operations
-14.6
-33.5
-52.6
-91.9
-109
-144
Capital expenditures
-0.2
-0.67
-5.55
-5.75
-1.31
-0.26
Purchases of investments
-24.2
-288
-292
-256
-477
-527
Sales and maturities of investments
43.2
197
344
278
Cash from investing
-24.4
-242
-70.6
103
-185
-32.8
Stock issued
0.2
0.11
129
52.6
239
187
Cash from financing
120
186
130
53.2
249
196
Net change in cash
81.3
-89.4
6.43
64.1
-44.4
19.5
Free cash flow
-14.8
-34.2
-58.2
-97.7
-110
-144
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $39.34 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-44.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-41.1%
Net income / average total assets.
Return on invested capital (ROIC)
-46.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
13.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
14.6%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
13.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
14.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
33.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
11.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
24.3%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
168.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
16.2x
Current assets / current liabilities.
Quick ratio
2.49x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.49x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$1.48
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.47
Cash from operations / diluted weighted shares.
Book value per share
$4.16
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
9.54x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
9.54x
Market cap / tangible book value, when positive.
FCF yield
-3.7%
Free cash flow / market cap.
Earnings yield
-4.6%
Net income / market cap (the inverse of P/E).
Was Edgewise Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $167.8M.
How much free cash flow did Edgewise Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $143.8M minus capital expenditures of $256.0K left free cash flow of -$144.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.